News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Teva Pharmaceutical Industries Limited (TEVA) Announces Launch of Generic ACTOplus met® in the United States


8/20/2012 9:18:03 AM

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today the launch of an authorized generic of ACTOplus met® (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg. ACTOplus met® is marketed by Takeda Pharmaceuticals U.S.A., Inc. and used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOplus met® had annual sales of approximately $413 million in the United States, based on IMS sales data as of June 30, 2012.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES